MBX Biosciences MBX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$2.86M (7 inflow days, 13 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 52.5% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 10.28% to 8.90% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +2,045,513 | 14.8% |
| BlackRock | Mutual Fund | 2026/Q3 | +149,775 | 7.0% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +93,383 | 0.3% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +90,963 | 0.2% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +67,971 | 1.7% |
| Sowell Financial Services, LLC | Mutual Fund | 2026/Q3 | +53,077 | 0.1% |
| Barclays PLC | Public Company | 2026/Q3 | +50,503 | 0.3% |
| Franklin Resources | Mutual Fund | 2026/Q3 | +40,552 | 0.6% |
| Paradigm Biocapital Advisors LP | Hedge Fund | 2026/Q3 | +2,508,015 | 5.1% |
| FMR | Mutual Fund | 2026/Q3 | +2,386,164 | 11.1% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +1,785,699 | 10.0% |
| BlackRock | Mutual Fund | 2026/Q3 | +382,266 | 6.9% |
| Marshall Wace LLP | Hedge Fund | 2026/Q3 | +339,182 | 0.8% |
| Soleus Capital Management, L.P. | Hedge Fund | 2026/Q3 | +336,382 | 1.0% |
| Bank of America Corporation | Public Company | 2026/Q3 | +270,177 | 0.6% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 9 Nov 2026 | Steven Hoerter | Executive Chairperson, CEO & President | Open Market Disposition | -4,893 | $54.82 | 27,045 |
| 3 Nov 2026 | Salomon Azoulay | Chief Medical Officer | Open Market Disposition | -373 | $53.96 | 1,839 |
| 19 Oct 2026 | Peter Radovich | Other Derivative Acquisition | +18,200 | $53.50 | 18,200 | |
| 16 Aug 2026 | Peter Hawryluk | Former Officer | Intent to Sell (Form 144) | -3,745 | $68.29 | – |
| 3 Aug 2026 | Peter Hawryluk | Former Officer | Intent to Sell (Form 144) | -936 | $65.77 | – |
| 3 Aug 2026 | Salomon Azoulay | Chief Medical Officer | Open Market Disposition | -370 | $65.77 | 14,399 |
| 2 Aug 2026 | John Smither | Chief Financial Officer | Other Acquisition | +28,000 | – | 28,000 |
| 2 Aug 2026 | John Smither | Chief Financial Officer | Other Derivative Acquisition | +130,000 | $64.41 | 130,000 |
| 2 Aug 2026 | Steven Hoerter | Executive Chairperson, CEO & President | Other Acquisition | +71,000 | – | 82,938 |
| 2 Aug 2026 | Steven Hoerter | Executive Chairperson, CEO & President | Other Derivative Acquisition | +331,000 | $64.41 | 331,000 |
| 9 Jun 2026 | Richard Bartram | Former Chief Financial Officer | Intent to Sell (Form 144) | -9,167 | $30.55 | – |
| 8 Jun 2026 | Richard Bartram | Former Chief Financial Officer | Intent to Sell (Form 144) | -10,833 | $29.66 | – |
| 3 Jun 2026 | Patrick Heron | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 3 Jun 2026 | Edward Mathers | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 3 Jun 2026 | Ora Pescovitz | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 3 Jun 2026 | Tiba Aynechi | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 3 Jun 2026 | Steven Ryder | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 3 Jun 2026 | Steven Hoerter | Executive Chairperson, CEO & President | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 3 Jun 2026 | Laurie Stelzer | Independent Director | Other Derivative Acquisition | +12,500 | $30.91 | 12,500 |
| 12 May 2026 | Richard Bartram | Former Chief Financial Officer | Intent to Sell (Form 144) | -15,000 | $36.95 | – |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 4,285,299 | 8.9% | 7.9 |
| 15 Oct 2026 | 4,422,964 | 9.2% | 7.5 |
| 30 Sep 2026 | 4,466,280 | 9.3% | 6.8 |
| 15 Sep 2026 | 4,129,859 | 8.6% | 11.4 |
| 31 Aug 2026 | 4,155,572 | 8.6% | 10.1 |
| 14 Aug 2026 | 4,950,102 | 10.3% | 11.2 |
No comments yet — be the first to weigh in on MBX.
Sign in to join the discussion.